ClinicalTrials.gg
RecruitingNCT04674020REFORMUpdated Jan 10, 2022

Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment

A Phase 4 interventional study of Erenumab in Migraine and Headache, sponsored by Danish Headache Center. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-10.

Sponsored by Danish Headache Center · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
250
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing erenumab in Migraine Disorders — 3 open to participants now, 4 under way, 1 of them phase 3. erenumab · Migraine Disorders.

Planned enrollment
20th of 37
250 · median 261
Started
2020
with 6 others
Phase 4
16 of 37
3 open now
Registered
33rd of 37
by date
Lead sponsor
4 of 37
Danish Headache Center

Among the 37 studies testing erenumab in Migraine Disorders, this one is the 20th largest by planned enrollment, is one of 7 that started in 2020, is one of 16 in phase 4, and was the 33rd registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

3 of the 37 studies testing erenumab in Migraine Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About erenumab

erenumab: first FDA approval 2018 (AIMOVIG), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing erenumab in Migraine Disorders, or all of them as a file.
02

Study summary

This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.

Read the detailed description

Migraine is a prevalent neurological disorder and a leading cause of years lived with disability worldwide. As of recent, therapies targeting calcitonin gene-related peptide (e.g. erenumab) have been approved for the preventive treatment of migraine. This study aims to investigate structural and functional cerebral changes using magnetic resonance imaging before and after treatment with erenumab in patients with migraine.

03

Conditions studied

  • Migraine
  • Headache
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Criteria:

Inclusion criteria

Inclusion Criteria:

  • Subject has provided prior to initiation of any study-specific activities/procedures
  • Age greater than or equal to 18 years upon entry into screening
  • History of migraine (with or without aura) for greater than or equal to 12 months before screening according to the International Headache Society (IHS) Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2018) based on medical records and/or patient self report
  • Greater than or equal to 4 headache days that meet criteria as migraine days per month on average across the 3 months before screening after baseline period
  • Must have demonstrated greater than or equal to 75% compliance in headache diary usage during baseline period

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from the study if any of the following criteria apply:

Disease Related

  • Greater than 50 years of age at migraine onset
  • History of cluster headache or hemiplegic migraine headache
  • Inability to differentiate between migraine from other headaches
  • The subject is at risk of self-harm or harm to others as evidenced by past suicidal behaviour
  • History or evidence of any other disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion Prior/Concomitant Therapy
  • Previously received erenumab (Aimovig®)
  • Received an anti-CGRP monoclonal antibody within 3 months prior to the start of the baseline period Prior/Concurrent Clinical Study Experience
  • Currently receiving treatment in another device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study (ies). Other investigational procedures while participating in this study are excluded.

Other Exclusions

  • Female subjects of with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test.
  • Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 16 weeks after the last dose of investigational product.
  • Female subjects of childbearing potential unwilling to use 1 acceptable method of effective during treatment and for an additional 16 weeks after the last dose of investigational product.
  • Evidence of current pregnancy or breastfeeding per subject self-report or medical records
  • Subject has known sensitivity to any of the products or components to be administered during dosing
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject and investigator's knowledge

to MRI:

  • Does not wish to be informed about unexpected MRI findings
  • Severe claustrophobia
  • Implanted magnetic material including pacemaker, prothesis, metal-clips, etc.
  • Insulin pump which cannot be removed
  • Magnetic foreign object in the body
  • Surgical intervention within 6 weeks prior to MRI
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Single-Arm

    Erenumab packed in a SureClick® Autoinjector Pen (AI).

    Drug: Erenumab

Interventions

  • Erenumab 70 mg or 140 mg packed in a SureClick® Autoinjector Pen (AI)

    Also known as: Aimovig

06

What researchers measure

Primary outcomes

  1. Headache Diary

    Headache diary with daily entries to record migraine-related data.

    Time frame: Baseline Phase (Day -42 to -28) to Month 6]

Secondary outcomes

  1. 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline

    * MP2RAGE * GRAPPATINI * Gradient-Recalled-Echo (GRE) Sequence w/wo Magnetization Transfer (MT) * MPRAGE * Diffusion Tensor Imaging (DTI) * Resting State Functional MRI * Task-Based Functional MRI (visual stimulation with checkerboard) * 3D FLAIR

    Time frame: Baseline Phase (Day -42 to -28)

  2. 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 6

    * MP2RAGE * GRAPPATINI * Gradient-Recalled-Echo (GRE) Sequence w/wo Magnetization Transfer (MT) * MPRAGE * Diffusion Tensor Imaging (DTI) * Resting State Functional MRI * Task-Based Functional MRI (visual stimulation with checkerboard) * 3D FLAIR

    Time frame: Week 24 ± 2 Weeks

  3. 3T Brain Structural and Functional Magnetic Resonance Imaging (MRI) at Baseline at Month 12

    * MP2RAGE * GRAPPATINI * Gradient-Recalled-Echo (GRE) Sequence w/wo Magnetization Transfer (MT) * MPRAGE * Diffusion Tensor Imaging (DTI) * Resting State Functional MRI * Task-Based Functional MRI (visual stimulation with checkerboard) * 3D FLAIR

    Time frame: Week 48 ± 4 Weeks

  4. Headache Diary

    Headache diary with daily entries to record migraine-related data.

    Time frame: Baseline Phase (Day -42 to -28) to Month 12

  5. Blood Specimen for Analysis of Biomarkers at Baseline

    * 31 mL Blood for Plasma * 16 mL Blood for Serum * 28 mL Blood for Heparinized Plasma

    Time frame: Baseline Phase (Day -42 to -28)

  6. Blood Specimen for Analysis of Biomarkers at Month 6

    * 31 mL Blood for Plasma * 16 mL Blood for Serum * 28 mL Blood for Heparinized Plasma

    Time frame: Week 24 ± 2 Weeks

  7. Blood Specimen for Analysis of Biomarkers at Month 12

    * 31 mL Blood for Plasma * 16 mL Blood for Serum * 28 mL Blood for Heparinized Plasma

    Time frame: Week 48 ± 4 Weeks

  8. Semi-Structured Interview

    In-person semi-structured interview to record migraine-related data.

    Time frame: Baseline Phase (Day -42 to -28)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Jul 2025, 57 months after the start.

Of 49 non-industry phase 4 interventional studies under Migraine Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 57 months is above that.

Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2020
First posted
Dec 17, 2020
StartActual
Oct 22, 2020
Primary completionEst.
Jul 22, 2025
CompletionEst.
Jul 22, 2025
Last update
Jan 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04674020
Responsible party
Messoud Ashina (Prinicipal Investigator, Danish Headache Center) — Principal investigator
First posted
Dec 17, 2020
Start date
Oct 22, 2020
Primary completion
Jul 22, 2025 (estimated)
Completion
Jul 22, 2025 (estimated)
Last update
Jan 10, 2022

Study contacts

Messoud Ashina, MD
Contact
ashina@dadlnet.dk
+45 38 63 33 85
Hakan Ashina, MD
Contact
ashinajudo@yahoo.dk
+45 38 63 20 61
Messoud Ashina, MD
principal investigator · Danish Headache Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Erenumab

Start the discussion